Inflammation-associated cancer: NF-kappaB is the lynchpin.
It has long been suspected that NF-kappaB signaling has a pivotal role in chronic inflammation-associated malignancies, although genetic evidence for this hypothesis has been lacking. However, recent papers have lent credence to this concept and show that NF-kappaB activation in pre-malignant cells contributes to cell survival and metastatic potential. Furthermore, NF-kappaB activation in tumor-associated leukocytes, especially macrophages, contributes towards tumorigenesis by upregulating tumor-promoting proinflammatory proteins. This emphasizes the importance of NF-kappaB inhibitors as immunotherapeutic agents for chronic inflammation and suggests that these reagents might prevent, or at least inhibit, chronic inflammation-associated tumorigenesis.
Li
Qiutang
Q
Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA. verma@salk.edu
Withoff
Sebo
S
Verma
Inder M
IM
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D007962:Leukocytes / Q000276:immunology / Q000473:pathology; D016328:NF-kappa B / Q000378:metabolism*; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D016328:NF-kappa B